Announcements Trials
Browse Landscape

Phase

Phase 1 12Phase 2 5Phase 1/2 5Phase 3 3Phase NA 2Phase EARLY_PHASE1 2Phase 2/3 2Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 9Prostatic Neoplasms 6Neoplasms 5Multiple Myeloma 5Neoplasm Metastasis 3Leukemia, Myeloid, Acute 3Leiomyoma 3Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Hematologic Neoplasms 2Glioma 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Vomiting 1Venous Thromboembolism 1Tuberous Sclerosis 1Thyroid Neoplasms 1Thyroid Diseases 1Thoracic Neoplasms 1Thalassemia 1Squamous Cell Carcinoma of Head and Neck 1Skin Substitutes 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Pulmonary Embolism 1Primary Myelofibrosis 1Post-operative Seroma Formation 1Polycythemia Vera 1Pituitary Neoplasms 1

Interventions

enfortumab vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Carcinoma, Transitional Cell × 30 days × Clear all
NCT06862219 2026-05-28

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

Astellas Pharma Inc

Phase 4 Recruiting
100 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡